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ABSTRACT 
Human frataxin is an iron binding protein involved in the mitochondrial Fe-S clusters 
assembly, a process fundamental for the functional activity of mitochondrial proteins. 
Decreased level of frataxin expression is associated with the neurodegenerative 
disease Friedreich ataxia. Defective function of frataxin may cause defects in 
mitochondria, leading to increased tumorigenesis. Tumour initiating cells show higher 
iron uptake, a decrease in iron storage and a reduced Fe-S clusters synthesis and 
utilization. In this study we selected, from COSMIC database, the somatic human 
frataxin missense variants found in cancer tissues p.D104G, p.A107V, p.F109L, 
p.Y123S, p.S161I, p.W173C, p.S181F, and p.S202F to analyze the effect of the single 
amino acid substitutions on frataxin structure, function and stability. The spectral 
properties, the thermodynamic and the kinetic stability, as well as the molecular 
dynamics of the frataxin missense variants found in cancer tissues point to local 
changes confined to the environment of the mutated residues. The global fold of the 
variants is not altered by the amino acid substitutions, however some of the variants 
show a decreased stability and a decreased functional activity in comparison to that of 
the wild type protein. 
Graphical abstract 
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Introduction 
In cancer cells metabolic activities are altered relative to normal cells. The metabolic 
reprogramming, and the consequent metabolic alterations, guarantees the acquisition 
of the malignant properties, necessary to enable the cancer cells to thrive despite the 
adverse conditions, like for example the oxygen deficiency (Kroemer and Pouyssegur, 
2008). In particular, the metabolism and bioenergetics of cancer cells is altered to 
support proliferation and malignant progression: the glycolytic flux is increased with 
respect to normal cells, and amino acid and lipid metabolisms are accelerated and 
upregulated. Overall, macromolecule biosynthesis and mitochondrial biogenesis, as 
well as cellular redox homeostasis, are perturbed (DeBerardinis et al., 2016; Liu et al., 
2019; Orang et al., 2019; Phan et al., 2014). Indeed, the process of tumorigenesis and 
mitochondrial biology interplays at multiple levels, ranging from direct oncogenic 
signaling from mitochondria to perturbation of mitochondrial functions, often caused 
by mutation in mitochondrial proteins (Sreedhar and Zhao, 2018). 
In this respect, mutations of proteins involved in the assembly of those mitochondrial 
proteins, like aconitase and complex I, II and III that depend on iron-sulfur clusters 
(Fe-S) for their functions, could be at the origin of cancer onset and responsible for its 
progression (Thierbach et al., 2005). Frataxin (FXN protein, coded by FXN gene: 
LRG_339), whose primary function is still under debate, is directly involved in the 
Fe-S cluster assembly inside the mitochondria (Thierbach et al., 2005) and since Fe-S 
clusters are important for the correct functioning of the mitochondrial proteins, 
frataxin impaired function may cause defects in mitochondria then leading to 
increased tumorigenesis (Thierbach et al., 2005). Indeed, it has been reported that 
tumour initiating cells show higher iron uptake, a decrease in iron storage and a 
reduced Fe-S clusters synthesis and utilization (Rychtarchikova et al., 2017). 
In the general reprogramming of cancer cell metabolism, iron viability is an essential 
requirement for the invasion. Notably, this is not only important for the cancer cells 
but also to its particular microenvironment constituted by different type of normal 
cells ranging from endothelial and stromal cells to macrophages (Torti and Torti, 
2011). Iron could simply be regarded as a tumour initiator because of its involvement 
in the production of DNA damaging oxygen radicals, which might increase the rate of 
mutagenesis (Torti and Torti, 2013). On the other hand, iron could be regarded as a 
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tumour growth factor when examined in the context of its cellular roles: cellular 
energy generation, increased rate of cellular cycle, and the increased demand of Fe-S 
clusters essential for the accelerated DNA metabolism (Torti et al., 2018). In 
synthesis, the multifaceted role of iron in cancer can be simply considered as 
beneficial and essential for tumour growth, as well as deleterious at the same time for 
its potentially toxic effects (Torti and Torti, 2013). 
Fe-S clusters are protein cofactors involved in several cellular processes from 
respiration to DNA replication and repair. The clusters are assembled in the presence 
of the pyridoxal dependent cysteine desulfurase (NFS1 in human), the iron delivery 
protein frataxin (FXN), reductant ferredoxin, and a scaffold protein (IscU) (Cai et al., 
2018). Decreased level of expression of the iron binding protein human frataxin 
(FXN) involved in Fe-S cluster assembly is associated with Friedreich ataxia (FRDA; 
MIM# 229300), a neurodegenerative disease characterized by neuronal death, 
cardiomyopathy and diabetes (Correia et al., 2008). The FXN deficiency, at the 
molecular level, is related to the deregulation of iron homeostasis and alteration of the 
Fe-S protein biogenesis (Correia et al., 2008). Notably, young patients affected by 
FRDA are also affected by different cancer type, unusual for their age, even though 
there is no evidence of a direct correlation between this disease and cancer (Schulz et 
al., 2006). 
Somatic mutations of FXN have been identified in various cancer types and reported 
in COSMIC (Catalogue of Somatic Mutations in Cancer) 
(http://cancer.sanger.ac.uk/cosmic), a database for the collection of somatic mutations 
identified in human cancers (Forbes, 2017). Among them, 23 out 32 single nucleotide 
substitutions are non synonymous single nucleotide variants (nsSNVs) in the FXN 
coding region leading to a protein sequence with amino acid substitutions.  
The effects exerted by somatic mutations on the proteins range from changes in the 
protein stability, to alterations in the protein functions and in protein-protein 
interactions (Pasquo et al., 2012; Lori et al., 2013; Lori et al., 2016; Stefl et al., 2013; 
Petrosino et al., 2017). Computational studies based on protein structural information 
may provide a rationale for the changes induced by mutation (Casadio et al., 2011, 
Petukh et al., 2015; Peng et al., 2019), however direct physico-chemical studies of the 
protein variants may reveal all the local minor structural changes responsible of 
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modifications in protein functions without dramatic alterations of the global protein 
folding (Lori et al., 2016). In addition, detailed experimental analysis may add new 
piece of information to computational research and motivate new studies.  
In this study eight nsSNVs of FXN present in cancer tissues were selected from those 
reported in COSMIC database (Fig. 1). The residues carrying the mutations are 
located in the alpha-1 helix close to the acidic region, presumably involved in iron 
binding on the protein surface, in the coil regions between alpha-1 and beta-1 and 
beta-4 and beta-5, respectively, and in the beta-6 and beta-7 strands (Dhe-Paganon et 
al., 2000) (Fig. 1). We report the effects for the eight FXN nsSNVs on 
thermodynamic stability by equilibrium and kinetic experiments and we study the 
impact of each mutation on FXN functional activity. 
Materials and Methods 
Site-directed mutagenesis  
pET28a plasmid harbouring the FXN wild-type gene was used for E. coli expression. 
The point mutations on wild type FXN gene were introduced using Quick Change 
Site-Directed Mutagenesis Kit (Stratagene). The mutagenic oligonucleotides used are 
listed in Supp. Table S1. The presence of the desired mutations and the absence of 
unwanted ones were confirmed by sequence analysis. 
Protein Expression and Purification  
FXN wild type and variants were expressed as N-terminally His-tagged proteins using 
a pET28a vector. Wild type and mutant proteins were expressed in E. coli Rosetta 
cells transformed with the selected plasmid, grown at 37°C in LB medium containing 
kanamycin as antibiotic at a final concentration of 30 µg/mL until optical density 
OD600 reached 0.6. The protein expression was induced overnight by adding 0.5 mM 
isopropyl-β-D-thiogalactoside (Sigma-Aldrich) and grown overnight at 18°C with 
energic shaking. The culture was harvested by centrifugation and resuspended in 40 
mL of Binding buffer (20 mM Tris-HCl, 500mM NaCl, 5 mM Imidazole, pH 8.0) 
containing 1 mM tris(2-carboxyethyl)phosphine (TCEP) in the presence of a cocktail 
of EDTA-free protease inhibitors (Sigma). The cells were sonicated in a Vibracell 
75115 sonicator with 5 s boots and 9 s pause, on ice and the lysate was cleared by 
centrifugation. The soluble fraction was applied to a 5mL pre-packed His trap column 
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(GE Healthcare) pre-equilibrated with Binding buffer. The column was washed with 
Binding buffer to elute weakly bound contaminants and the recombinant protein was 
eluted by passing over the column Binding buffer solutions containing 250 mM 
Imidazole. The eluted protein was concentrated to a final volume of 2.5 mL on an 
Amicon concentrator Ultra-15 (Millipore) and then applied to a PD-10 pre-packed 
column (GE Healthcare) to remove imidazole. The pure fraction in Binding buffer 
was incubated overnight at 4°C with tobacco etch virus (TEV) protease to cleave the 
hexahistidine tag. After digestion, the mixture containing TEV protease, the His-tag 
and the cleaved protein was applied to a 5 mL pre-packed His Trap column (GE 
Healthcare) previously equilibrated in Binding buffer. The flow through containing 
the protein without His-tag was collected, and purity and size were checked by SDS–
PAGE on a pre-casted NuPage 4–12% bis-Tris polyacrylamide gel (Invitrogen). 
Protein concentration was determined spectrophotometrically using a molar 
absorptivity of 26930 M−1 cm-1 at 280 nm based on a molecular mass of 13.886 kDa. 
Spectroscopic measurements 
Intrinsic fluorescence emission spectra were recorded from 300–450 nm (at 295 nm 
excitation wavelength, 1 nm sampling interval), at 50.0 μg/mL protein concentration 
in 20 mM Tris/HCl, pH 8.0 containing 0.1 M NaCl, 1mM EDTA and 200 μM DTT 
with a LS50B spectrofluorimeter (Perkin-Elmer). Fluorescence measurements were 
carried out using a 1.0 cm path length quartz cuvette at 20°C. Far-UV (190–250 nm) 
CD spectra were recorded either at a protein concentration ranging over 100–140 
μg/mL (0.4 mM DTT, 0.1 cm path length quartz cuvette), corresponding to an 
absorbance of the protein solutions at 280 nm of 0.24 AU, either at a protein 
concentration ranging over 50–60 μg/mL (0.2 mM DTT, 0.2 cm path length quartz 
cuvette), corresponding to an absorbance of the protein solutions at 280 nm of 0.10 
AU. For near-UV (250–320 nm) CD spectra, the absorbance of the protein solutions 
at 280 nm was 2.2 AU, corresponding to a protein concentration ranging over 1.0–1.3 
mg/mL (1.0 mM DTT, 1.0 cm path length quartz cuvette). CD measurements were 
performed in a Jasco-815 spectropolarimeter (Jasco, Easton, MD, Usa) and the results 
obtained were expressed as the mean residue ellipticity [Θ], assuming a mean residue 
molecular mass of 110 per amino acid residue. All spectroscopic measurements were 
carried out at 20°C in 20 mM Tris/HCl, pH 8.0 containing 0.1 M NaCl, 1mM EDTA 
and 200 μM or 1 mM DTT.  
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Urea-induced equilibrium unfolding. 
For equilibrium transition studies, FXN wild type and variants (final concentration 
50.0 μg/mL) were incubated at 20 °C at increasing concentrations of urea (0−9 M) in 
20 mM Tris/HCl, pH 8.0, in the presence of 0.1 M NaCl, 1mM EDTA and 200 μM 
DTT. After 10 min, equilibrium was reached and intrinsic fluorescence emission and 
far-UV CD spectra (0.2-cm cuvette) were recorded in parallel at 20 °C. To test the 
reversibility of the unfolding, FXN wild-type and variants were unfolded at 20 °C in 
9.0 M urea at 0.5 mg/mL protein concentration in 20 mM Tris-HCl, pH 8.0, in the 
presence of 2 mM DTT and 0.1 M NaCl. After 10 min, refolding was started by 10-
fold dilution of the unfolding mixture at 20 °C into solutions of the same buffer used 
for unfolding containing decreasing urea concentrations. The final protein 
concentration was 50 μg/mL. After 24 h, intrinsic fluorescence emission and far-UV 
CD spectra were recorded at 20 °C. All denaturation experiments were performed in 
triplicate. 
Stopped-flow folding kinetics experiments 
Kinetic folding experiments were performed on a single-mixing SX-18 stopped-flow 
instrument (Applied Photophysics); the excitation wavelength was 280 nm and the 
fluorescence emission was collected using a 320 nm cut-off glass filter for unfolding 
experiments and a 360 nm cut-off glass filter for refolding experiments. Experiments 
were conducted at 37°C, and the buffer used was Tris-HCl 50mM, NaCl 100mM, 
DTT 1mM, pH 8.0, and different concentrations of urea, ranging from 0 to 8 M. At 
least 5 individual traces were acquired and then averaged for each experiments. 
Protein concentration was typically 2 µM. 
Thermal denaturation experiments. 
FXN wild type and variants (protein concentration ranging over 100–140 μg/mL) 
were heated from 20°C to 95°C and then cooled from 95°C to 20°C in a 0.1 cm quartz 
cuvette with a heating rate of 1.0 degree x min-1 controlled by a Jasco programmable 
Peltier element. The dichroic activity at 222 nm and the PMTV were continuously 
monitored in parallel every 0.5°C (Benjwal et al., 2006). All the thermal scans were 
corrected for the solvent contribution at the different temperatures. Melting 
temperature (Tm) values were calculated by taking the first derivative of the ellipticity 
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at 222 nm with respect to temperature. All denaturation experiments were performed 
in triplicate. 
Molecular Dynamics 
Molecular Dynamics (MD) simulations were performed with the GROMACS 
package (Berendsen et al., 1995; Lindahl et al., 2001; Van der Spoel et al., 2005; Hess 
et al., 2008). The initial coordinates of the wild type protein were taken from the 
crystal structure of the FXN (Dhe-Paganon et al., 2000) (PDB ID: 1EKG). The 
coordinates of the seven variants were obtained from the wild type coordinates by 
performing a single amino acid mutation by using PyMOL (The PyMOL Molecular 
Graphics System). Each system was placed in a cubic box of dimensions such that 
nearby images lay more than 10 Å away. The box was filled with water molecules and 
an appropriate number of counterions to make the whole system neutral. The 
AMBER03 force field (Duan et al., 1999) was used to simulate wild type FXN and all 
its variants. The equilibration strategy adopted for the eight systems is quite standard 
and is explained in detail in (Petrosino et al., 2017; Di Carlo et al., 2015). The 
temperature, for the production simulations, was held fixed at 300 K and 355 K using 
the v-rescale thermostat (Bussi et al., 2007) with a coupling time of 0.1 ps. The simple 
point charge (SPC) model was employed for water molecules. Periodic boundary 
conditions were used throughout the simulation. The Particle Mesh Ewald algorithm 
(Darden et al., 1993) was employed to treat Coulomb interaction. A time step of 2 fs 
and a non-bond pair list cutoff of 1.0 nm were used. The list was updated every 10 
steps. Each one of the eight systems was simulated for 150 ns (at 300 K) and 200 ns 
(at 355 K) in the NVT ensemble. The analysis of the numerical data obtained in the 
simulation was carried out by GROMACS and VMD (Humphrey et al., 1996) tools 
according to needs.  
Reconstitution experiments 
Enzymatic cluster formation was achieved under strict anaerobic conditions in a Belle 
chamber kept under nitrogen atmosphere. The reaction was followed by absorbance 
spectroscopy using a Cary 50 Bio Spectrophotometer (Varian). Absorbance variations 
at 456 nm was measured as a function of time. A solution of 3 mM DTT, 1μM IscS, 
50 μM IscU, of 50 μM of FXN wild type or mutated and 25 μM Fe(NH4)2(SO4)2 was 
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incubated in sealed cuvette for 30 minutes in 20 mM Tris-HCl pH 8, 150 mM NaCl. 
The reaction was initiated by adding 250 μM of the substrate L-cysteine. 
Crosslinking 
A mixture of IscS 40 μM and 40 μM FXN wild type or mutated was prepared in PBS 
buffer. Dimethyl adipimidate or Bis[sulfosuccinimidyl]suberate was added to the 
protein sample to a final concentration of 2 mM. The reaction mixture was incubated 
at room temperature for 30 minutes and quenched by adding Tris-HCl at pH 8 to a 
final concentration of 20 mM. The quenching reaction was incubated at room 
temperature for 15 minutes. SDS PAGE was run to determine crosslinked species. 
Data analysis 
The changes in intrinsic fluorescence emission spectra at increasing urea 
concentrations were quantified as the intensity-averaged emission wavelength, ( )λ , 
(Royer et al., 1993) calculated according to 
 ( ) /  ( )i i iI Iλ λ= Σ Σ  (1) 
where λi and Ii are the emission wavelength and its corresponding fluorescence 
intensity at that wavelength, respectively. This quantity is an integral measurement, 
negligibly influenced by the noise, which reflects changes in the shape and position of 
the emission spectrum. Urea-induced equilibrium unfolding transitions monitored by 
far-UV CD ellipticities changes was analysed by fitting baseline and transition region 
data to a two-state linear extrapolation model (Santoro and Bolen, 1988) according 
to:                                      
 [ ]2H Ounfolding unfolding TG G m Urea R lnK∆ = ∆ + = −  (2) 
where ΔGunfolding is the free energy change for unfolding for a given denaturant 
concentration, ΔGH2O the free energy change for unfolding in the absence of 
denaturant and m a slope term which quantifies the change in ΔGunfolding per unit 
concentration of denaturant, R the gas constant, T the temperature and Kunfolding the 
equilibrium constant for unfolding. The model expresses the signal as a function of 
denaturant concentration: 
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H O
i i i
i H O
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y s X y s X G m X RT
y
G m X
RT
 + + + −∆ − =
 −∆ −
 +
  
 (3) 
where yi is the observed signal, yU and yN are the baseline intercepts for unfolded and 
native protein, sU and sN are the baseline slopes for the unfolded and native protein, 
[X]i the denaturant concentration after the ith addition, ΔGH2O the extrapolated free 
energy of unfolding in the absence of denaturant, m the slope of a ΔGunfolding versus 
[X] plot. The denaturant concentration at the midpoint of the transition, [Urea]0.5, 
according to equation 2, is calculated as: 
 [ ] 2                                                         0.
H O
5
                        Urea /G m= ∆  (4)  
All unfolding transition data were fitted by using Graphpad Prism 5.04. 
Far-UV CD spectra recorded as a function of urea concentration were analyzed by a 
singular value decomposition algorithm (SVD) using the software MATLAB (Math-
Works, South Natick, MA) to remove the high frequency noise and the low frequency 
random errors and to determine the number of independent components in any given 
set of spectra. CD spectra in the 213–250 nm or in the 250-320 nm region were placed 
in a rectangular matrix A of n columns, one column for each spectrum collected at 
each time. The A matrix is decomposed by SVD into the product of three matrices: A 
= U*S*VT, where U and V are orthogonal matrices and S is a diagonal matrix. The U 
matrix columns contain the basis spectra and the V matrix columns contain the urea 
dependence of each basis spectrum. Both U and V columns are arranged in terms of 
decreasing order of the relative weight of information, as indicated by the magnitude 
of the singular values in S. The diagonal S matrix contains the singular values that 
quantify the relative importance of each vector in U and V. The signal-to-noise ratio is 
very high in the earliest columns of U and V while the random noise is mainly 
accumulated in the latest U and V columns. The wavelength averaged spectral 
changes induced by increasing denaturant concentrations are represented by the 
columns of matrix V; hence, the plot of the columns of V versus the denaturant 
concentrations provides information about the observed transition. 
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Results 
The eight human frataxin (FXN) variants, associated to human carcinoma and 
reported in this study (Fig. 1), were mined from the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic) (Forbes, 2017). The variant p.D104G is reported 
to be present in liver carcinoma, p.A107V, p.Y123S and p.W173C are reported in 
carcinoma from diverse locations of the digestive tract, p.F109L and p.S161I from 
endometrium carcinoma and p.S181F and p.S202F from skin malignant melanoma 
and carcinoma, respectively. In Fig. 1 is reported the location of the selected mutants 
mapped onto the FXN structure. It is noteworthy that most of the mutated residues are 
solvent exposed. Residues Asp104, Ala107 and Phe109 are located in the alpha1 
helix, which belongs to the FXN acidic region (Gomes and Santos, 2013; Foury et al., 
2007) formed at the interface with strand beta1, a region placed at the protein surface 
and presumably involved in iron binding (Foury et al., 2007). The residues Tyr123 
and Ser161, located in the coils between helix alpha1 and strand beta1, and beta5 and 
beta6, respectively, are both the last coil residues prior to the next strand. Residues 
Trp173 and Ser181 belong to strand beta6 and beta7, respectively, and Ser202 is 
located in the turn at the C-terminus. Notably, the residues Tyr123 and Trp173 (Galea 
et al., 2016 for review) are mutated in Freidreich ataxia (FRDA; MIM# 229300), and 
reported in COSMIC. For each of the identified mutant we generated recombinant 
protein using site directed mutagenesis. With the exception of p.W173C, all mutations 
resulted in soluble recombinant proteins and allowed us to investigate the results of 
the single amino acid substitution on the FXN thermal and thermodynamic stability 
and the biological activity. 
Spectroscopic characterization of FXN wild-type and variants 
To evaluate the effect of the FXN variants found in cancer tissues on the protein 
conformation in solution, spectroscopic analysis was performed using CD and 
fluorescence spectroscopy. The spectral contributions of all aromatic residues present 
in FXN wild type are evidenced in the near-UV CD spectrum that is characterized by 
an intense negative peak between 260 and 270 nm and by two other negative 
contributions at around 285 and 295 nm (Fig. 2A). Most of the variants display near-
UV CD spectra almost identical to that of the wild type with slight differences in the 
intensity of the peaks suggesting that their tertiary structure arrangements are similar 
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
respect to that of the corresponding wild type protein. The most significant alterations 
in the intensity of the negative contributions are observed in the near-UV CD 
spectrum of p.Y123S variant that shows a significant decrease of the dichroic activity 
specially in the region between 265-285 nm, a region where the typical spectral 
contribution of tyrosine is expected. In line with the near-UV CD results, the 
fluorescence emission spectra of variants are similar to that of wild-type protein. They 
show the same maximum emission wavelength around 343 nm, with a decreased 
emission fluorescence intensity (Fig. 2B) with respect to that of the wild type. 
Far-UV CD spectra of FXN wild type and variants show local minima at around 208 
and 220 nm and a zero intercept at around 200 nm, indicating the major contribution 
of alpha helical secondary structural elements, slightly influenced by the contribution 
of β sheet (Fig. 2C). As judged by the shape and the intensities of the signals, the 
secondary structure of the FXN variants is similar to that of the wild type (Fig. 2C) 
suggesting that the effect of the point mutations are mainly directed and localized to 
the mutated residue with minor modification of tertiary and secondary arrangements. 
The 222/208 ellipticity ratio gives information about interhelical contacts and is 
generally used to distinguish between coiled coil helices and non-interacting helices 
(<0.9) (Choy et al., 2003; Kiss et al., 2003). The ratio of the molar ellipticity at 222 
and at 208 nm ([Θ]222/[Θ]208) observed for the wild type is 0.70 and is quite similar 
for the variants ranging from 0.69 for p.D104G, to 0.75 for p.Y123S, suggesting that 
the single amino acid substitutions do not alter interhelical interactions in solution. 
Thermal and thermodynamic stability studies 
The thermal stability of FXN wild-type and variants was investigated by continuously 
monitoring the ellipticity changes at 222 nm between 20 and 95°C (Supp. Figure S1) 
and between 95 and 20°C (data not shown). By monitoring the temperature-induced 
ellipticity changes at 222 nm, where the main amplitude was observed, an apparent 
cooperative transition for FXN wild type and all the variants was observed, with 
apparent Tm values ranging from 56.0 to 73.0°C. The thermal unfolding transitions 
were reversible as judged by the signals upon cooling protein solutions to the starting 
temperature. As reported in Table 1, a modest increase in Tm value was observed for 
p.D104G and p.S202F variants, whereas all the other variants show a significant 
reduction of the Tm values ranging from 3 degrees below that of the wild type, as in 
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the case of p.A107V, to 14 degrees below that of the wild type, as in the case of 
p.Y123S. 
The impact of point mutations on the thermodynamic stability of FXN was 
investigated at 20°C in the presence of urea as a chemical denaturing agent. FXN wild 
type and variants reversibly unfold in urea in 20 mM Tris-HCl, pH 8.0, containing 0.1 
M NaCl, 1mM EDTA and 200 µM DTT with an apparent two-state cooperative 
sigmoidal transitions (Fig. 3). The effect of increasing urea concentrations (0–9 M) on 
the structure of FXN variants was analyzed by far-UV CD and intrinsic fluorescence 
spectroscopy. Incubation of FXN wild type and variants at increasing urea 
concentrations at 20°C resulted in a progressive change of the intrinsic fluorescence 
emission intensity and a red-shift of the maximal emission wavelength. At the end of 
the transition, above 9 M urea, the intrinsic fluorescence emission intensity is 
increased about 1.5 fold and the maximal fluorescence emission wavelength shifts 
from around 343 nm to around 357 nm either for the wild type and all the variants 
(Fig. 3A). The intrinsic fluorescence emission changes were expressed by calculating 
the intensity averaged emission wavelength, ( )λ , at increasing urea concentration 
(Fig. 3A). This parameter is an integral measurement, negligibly influenced by the 
noise, and reflects changes in both the shape and the position of the emission 
spectrum.  
The urea induced unfolding transitions monitored by far-UV CD (Fig. 3B) are 
coincident with those obtained by monitoring fluorescence changes. The 
thermodynamic parameters obtained from the analysis of the far-UV CD and 
fluorescence changes transitions are reported in Table 1. p.D104G and p.S202F show 
conformational stability closely similar to that of the wild type, whereas the free 
energy change for unfolding in the absence of denaturant, ∆GH2O, indicates a 
significant decrease in thermodynamic stability of 2–4 kcal/mol for of p.F109L, 
p.Y123S, p.S161I and p.S181F and an increase of about 1 kcal/mol for p.A107V 
variant. The changes in m values may indicate differences in the solvent exposed 
surface area upon unfolding between the variants and the wild type: decrease in m 
values is usually referred to a decrease in the solvent-exposed surface area upon 
unfolding. This is frequently ascribed to an increase in the compactness of the residual 
structure in the non-native state ensemble, rather than to an increase of the accessible 
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surface area of the native state (Pradeep and Udgaonkar, 2004; Wrabl and Shortle, 
1999). 
Thermodynamic stability data obtained by monitoring far-UV CD and fluorescence 
changes as a function of urea concentration have been compared with those obtained 
by computing the changes in folding free energy for each variant utilizing the servers 
PoPMuSiC (Dehouck et al., 2011) and I-Mutant 2.0 (Capriotti et al., 2005) (Supp. 
Table S2). The data reported in Supp. Table S2 are expressed as the difference in the 
free energy change upon unfolding of the variant and that of the wild type, ∆∆G; thus, 
a negative ∆∆G value < -1.0 kcal/mol indicates that the mutation is destabilizing. 
Notably, for the variants p.F109L, p.Y123S, p.S161I and p.S181F there is a general 
agreement between the experimental data and the predicted ∆∆G values, with the 
exception of p.S161I (Supp. Table S2). 
Folding Kinetics 
In order to better understand the folding of FXN wild type and variants we resorted to 
perform kinetic experiments. In an effort to fully characterize the folding properties of 
FXN and its variants we performed stopped-flow kinetic unfolding and refolding 
experiments, at different concentrations of urea ranging from 0 to 8 M, in 50 mM 
Tris-HCl, 100 mM NaCl, 1 mM DTT, pH 8.5, at 37°C. In all the experiments, the 
kinetics of folding and unfolding were perfectly described by a single exponential 
behaviour, an aspect that is usually interpreted with the absence of stable 
intermediates accumulating in the ms to s time range. The dependences of the 
logarithm of the observed rate constants versus the concentration of urea (chevron 
plot) for wild type is reported in Fig. 4. In a simple two-state folding mechanism, the 
resulting chevron plot presents a typical V-shape with the logarithm of the observed 
rate constants of the unfolding and refolding arms increasing and decreasing linearly 
as the concentration of urea changes. However, as it might be noted from inspection 
of Fig. 4, the arms of the chevron plot of wild type FXN deviate from linearity, which 
suggests the presence of a more complex scenario. In a previous work (Bonetti et al., 
2014) the folding kinetics of yeast frataxin were extensively characterized. The 
chevron plots obtained for yeast frataxin presented a curvature in both the unfolding 
and refolding arms and were fitted with an equation that describes a folding pathway 
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characterized by the presence of a broad energy barrier in the transition state 
(Oliveberg et al., 1998).  
 [ ] [ ]( ) [ ] [ ]( )
2 2
0 0 f u
m UREA m UREA m UREA m UREA
obs f uk k e k e
− + ′+ ′
= × + ×  (5)  
Thus, we resorted to compare folding kinetics data of the wild type FXN with the 
ones obtained from the yeast FXN, which returned an excellent fit (Fig. 4A). This 
result suggests that the folding of the human variant of FXN can be described with a 
comparable mechanism. 
Then we performed kinetic folding experiments on the variants of FXN. The resulting 
chevron plots are reported in Fig. 4B. A global fit was performed to analyse data, 
sharing the mu and mf values for all the data sets, which, as Fig. 4B reports, returned 
an excellent fit for every variant analysed, suggesting that mutations inferred to the 
protein do not have any effect on the folding mechanism of FXN. Kinetic data 
obtained from the fit are shown in Table 2. Analysis of kinetic data allowed us to 
calculate the difference in free energy between the native and denatured state in 
absence of denaturant as 
 ∆𝐺𝑁−𝐷 = 𝑅𝑇 ln 𝑘𝑓 𝑘𝑢⁄  (6) 
Results reveal that some mutations clearly affect the stability of FXN, with the ∆GN-D 
values obtained from kinetics being in good agreement with the ΔGH2
O values 
obtained from equilibrium fluorescence experiments. 
Functional activity 
It is well reported in literature that frataxin effects on the Fe-S cluster enzymatic 
constitution are caused by its binding to the desulfurase (IscS in this case). The 
functional ability of the FXN variants was compared to that of the wild type protein 
and to this purpose we used bacterial desulfurase IscS, using high sequence 
conservation between human desulfurase NFS1 and bacterial IscS. It was previously 
demonstrated that the two systems are functionally interchangeable, except that 
frataxin works as an inhibitor in bacteria and as an activator in eukaryotes. This 
functional inversion resides in the desulfurase (Bridwell-Rabb et al., 2012) which has 
a distinct assembly in the two families of organisms (Cory et al., 2017, Boniecki et al., 
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2017). Hence, we expected to see an effect that could be compared among the 
mutants. In order to prove the interaction, first a chemical cross-linking assay was 
performed to test the binding ability of the mutants. Bis[sulfosuccinimidyl]suberate, 
BS3, a cross-linking agent that reacts with primary amino groups, was added to a 
mixture containing IscS and each FXN mutant in PBS. SDS-PAGE revealed that a 
new species at around 58KDa that corresponds to FXN-IscS covalently bound is 
present, even if in small amount (Fig. 5).  
We then checked the ability of the mutants to modulate the activity of IscS. Enzyme 
activity was measured using E. coli Isc proteins IscS and IscU. This in vitro assay is a 
sensitive method to follow the enzymatic rates by detecting the absorbance as 
function of time. As shown by Bridwell-Rabb, addition of FXN to the IscS/IscU 
system inhibited Fe-S assembly less efficiently than bacterial frataxin, CyaY 
(Bridwell-Rabb et al., 2012). Proteins were mixed with 25 µM Fe2+ and 3 mM DTT in 
20 mM Tris-HCl, 150mM NaCl under inert atmosphere of nitrogen to avoid 
oxidation. After 30 minutes, when the system was equilibrated, 250 µM cysteine was 
added to start the reaction. Fe-S cluster formation was then easily followed by 
measuring the change in absorbance at the specific wavelength at 456 nm because this 
is the characteristic wavelength for the absorbance of Fe-S cluster on IscU. The 
concentration of IscU was set to 50 µM which is a value that allows easy 
measurement of the absorbance signal from the cluster. IscS was set to catalytic 
concentration of 1µM and FXN at 50 µM because at this concentration it did not 
significantly change the desulfurase activity (Bridwell-Rabb et al., 2012).  
Introduction of FXN wild type does not produce appreciable effects on the enzymatic 
rates (Fig. 6). On the contrary, its variants p.D104G, p.A107V, p.S161I, p.S181F and 
p.S202F remarkably inhibits the kinetic at the point that no Fe-S cluster is detected 
(Fig. 6). On the other side p.F109L and p.Y123S have only a partial inhibitor effect 
on the Fe-S cluster formation (Fig. 6). 
Overall these results confirm that FXN is able to affect the Fe-S cluster formation by 
interacting with IscS. We investigated FXN carrying different missense mutations, as 
identified in disease, with an inversion of polarity or change of steric effect. When a 
non-polar or a charged aminoacid is changed to one with polar characteristics (Ser 
with Ile or Phe or Asp with Gly) the effect on the kinetic is more pronounced as well 
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as with the replacement of a smaller residue with one of different steric characteristics 
(Ala with Val). A minor, but still remarkable, effect is observed when an aromatic 
residue is mutated to one with an aliphatic side chain (Phe with Leu or Tyr with Ser). 
Molecular dynamics 
MD simulations give us atomistic (microscopic) information on what is observed at 
the macroscopic level, thus they may be very helpful in the interpretation of 
experimental data. 
The stability of the eight models, both in the simulation at 300 K and in that at 355 K, 
is assured by the stability of the root mean square displacement (r.m.s.d.) and the 
radius of gyration, shown in Supp. Figures S2 and S3, respectively. In Table 3 we 
report the values of r.m.s.d. and the radius of gyration of the simulated systems 
averaged respectively over the last 50 ns/100 ns of the 300 K/355 K simulation. The 
radius of gyration is identical (within errors) for all the systems, while the r.m.s.d. 
values of p.D104G and p.S161I at 300 K and of p.S202F at 355 K are smaller than 
that of the wild type thus meaning that the three mutants are more similar to the 
starting structure than the wild type. 
In Supp. Figure S4 the root mean square fluctuations (r.m.s.f.) for the side chains of 
the simulated proteins are shown. At 300K (left side of Supp. Figure S4), we observe 
the highest mobility nearby residue 140 (for most of the simulated systems) and in the 
segment 176-179 for p.S181F and p.S202F variants. At 355 K, one of the most 
fluctuating systems is the wild type one, around residue 140 and at the C-terminal. 
Experimental data show that variants p.D104G, p.A107V, p.S161I, p.S181F and 
p.S202F remarkably inhibit Fe-S cluster formation while p.F109L and p.Y123S 
inhibit the process only partially. Since FXN binding to the desulfurase (IscS) is 
known to have effects on the Fe-S cluster enzymatic constitution, to obtain 
information on the propensity of the variants to interact with IscS, we computed (for 
wild type and the seven variants) the solvent accessible surface area (SASA) for the 
side chains of the FXN residues potentially involved in the interaction (Prischi et al., 
2010). 
As shown in Supp. Figure S5, the main differences between wild type and its mutants 
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are in the side chains SASA of the residues 136 and 140, for all the mutants except 
p.Y123S, for which only residue 136 is less accessible and p.S181F for which there 
are not differences with respect to wild type.  
Since higher SASA values correspond to greater exposure of the amino acids and to 
larger distances between amino acids within the protein, we evaluated the distances 
between Leu136-Ala193 (d1), Leu140-Ala93 (d2) and Leu140-Leu194 (d3). In Table 
4 we report the average values of the three distances computed along the last 50 ns of 
the simulations at 300 K. As expected, we observe that the values of three distances 
are significantly different from the values they assume in the wild type samples for all 
variants except p.Y123S and p.S181F. 
The present results indicate that the inhibition of Fe-S cluster formation may depend 
on the weaker interaction of the mutants, and in particular of Leu136 and Leu140, 
with respect to wild type FXN with IscS. From MD data analysis it turns out that the 
only two mutants that have the same behaviour as wild type FXN (with respect to the 
interaction with IscS) are p.Y123S and p.S181F. On the contrary, considering the 
SASA of the residues involved in the interaction with IscU (Cai et al., 2018) it turns 
out that Trp155 is less exposed to the solvent (has a smaller SASA value than the wild 
type) only in p.Y123S and p.S181F thus possibly meaning that the two mutants have 
a weaker interaction than all the other mutants (and the wild type) with IscU. 
MD data analysis point out that despite there are no significant differences in 
secondary structure (data not shown), r.m.s.d. and gyration radius between wild type 
FXN and its mutants, Leu136 and Leu140 may be important in the interaction with 
IscS and hence in FXN involvement in Fe-S cluster formation. 
DISCUSSION 
The mitochondrial protein frataxin (FXN) is expressed in several tissues, in particular 
liver, adrenal, bone marrow, heart and skin (Campuzano et al., 1996). The function of 
this protein is still under debate and, amongst various hypotheses, the involvement in 
iron binding as a component of the Fe-S cluster assembly complex is the most 
supported by experimental evidence (Pastore and Puccio, 2013).  
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The biosynthesis of Fe-S clusters is necessary for normal functions of human 
mitochondria and defects in their complex assembly mechanism, which involves at 
least 18 proteins, have been associated with a number of different diseases (Cai et al., 
2018). As a matter of fact, Fe-S clusters are required for the correct functioning of 
proteins involved in several cellular activities ranging from electron transport in 
respiratory chain complexes to DNA repair (Rouault, 2012). The defects of Fe-S 
clusters assembly in mitochondria influence a great number of extra-mitochondrial 
pathways, as seen for example in the nucleus for DNA synthesis and repair, or in the 
cytosol for the synthesis of ribosomal proteins and, in general, in cellular iron 
regulation and homeostasis (Stehling et al., 2014). 
FXN gene does not seem to possess cancer driver properties (Davoli et al., 2013), and 
an increased risk of tumour has been apparently excluded in Friedreich ataxia (FRDA) 
patients (Bürk, 2017; Martelli et al., 2012). However, alteration of FXN levels has 
been found in different types of cancer, as reported in the Cancer Genome Atlas 
(Hutter and Zenklusen, 2018), and several cases of FRDA are associated with the 
occurrence of neoplastic diseases and alteration of DNA in peripheral blood cells 
(Ackroyd at al., 1996; Ramos et al., 1997, Kidd et al., 2001, Deutsch et al., 2012, 
Misiakos et al., 2011, Barr et al, 1984; Haugen et al., 2010). Notably, alteration of 
iron homeostasis (Rychtarchikova et al., 2017) and perturbation of the redox 
equilibrium, as well as of the macromolecule biosynthesis and mitochondrial 
biogenesis (DeBerardinis et al., 2016; Phan et al., 2014), are concomitant to the 
general reprogramming of cancer cell metabolism (DeBerardinis et al., 2016; Phan et 
al., 2014). Indeed, it has been reported that FXN impaired function may cause defects 
in mitochondria then leading to increased tumorigenesis (Thierbach et al., 2005). 
However, the role of frataxin in cancer onset and progression could only be indirect, 
e.g. related to the genomic instability caused by defective biosynthesis of Fe-S cluster 
specific for DNA-repair enzyme (Thierbach et al., 2010; Tsai and Barondeau, 2010). 
On the other hand, hypoxia mediated increase of FXN expression may protect against 
oxidative stress and apoptosis, and suggest a tumour suppressor function for this 
protein (Guccini et al., 2011). The interconnection between alteration in iron 
metabolism and cancer is further evident from the fact that several variants of human 
mitochondrial ferritin, a protein that may rescue the defects caused by FXN silencing 
(Zanella et al., 2007; Campanella et al., 2004), are present in the same cancer tissues 
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and cell lines where also FXN variants are reported to be present (Hutter and 
Zenklusen, 2018).  
For this study, we selected from COSMIC database 
(http://cancer.sanger.ac.uk/cosmic) (Forbes et al., 2017) some somatic FXN non 
synonymous single nucleotide variants (nsSNVs) found in cancer tissues. In these 
variants, the mutations mainly involve surface residues, exposed to the solvent (Fig. 
1). Three out of them, are located at the alpha-1 and beta-1 interface and presumably 
involved in iron binding in the acidic binding region of FXN (Gomes and Santos, 
2006). None of the residues mutated in the cancer associated variants is placed in a 
conserved position (Dhe-Paganon et al., 2000). Notably, two residues mutated in the 
variants reported in COSMIC database, Tyr123 and Trp173, are also mutated in 
FRDA (Galea et al., 2016). However, the mutations observed in FRDA, p.Y123D and 
p.W173G, are different from those reported in COSMIC and object of this study (Fig. 
1). 
The thermodynamic stability of the missense variants p.F109L (Supp. Figure S8), 
p.Y123S (Supp. Figure S9), p.S161I (Supp. Figure S10), and p.S181F (Supp. Figure 
S11), is decreased in comparison to that of the wild type and is unchanged for 
p.D104G, where a charged polar residue is mutated into a hydrophobic one (Supp. 
Figure S6), for p.S202F (Supp. Figure S12), where a polar residue is substituted by a 
hydrophobic one and for p.A107V (Supp. Figure S7), where there is a steric 
difference between the two hydrophobic residues involved. To rationalise the effect of 
the mutations on the thermodynamic parameters, we analysed the interactions in the 
protein structure of the residues mutated in cancer tissues. In the case of Phe109, the 
aromatic ring is involved in a network of hydrophobic interactions with Phe110, 
Leu113 and Leu200 that might be hampered by the substitution of the phenylalanine 
benzene ring with the aliphatic side chain of leucine, in particular for the lack of the pi 
interaction with Phe110 (Supp. Figure S8). Indeed, MD simulations show that the 
distance between residue Leu109 (in p.F109L) and Leu200 is significantly larger than 
in the wild type. Tyr123 residue is involved in a pi-alkyl hydrophobic interaction, that 
requires the presence of an aromatic ring, with the methyl group of Ala114, the first 
residue at the end of the alpha1 helix (Supp. Figure S9). In addition, the hydroxyl 
group of Tyr123 is hydrogen bonded to the peptide carbonyl group of Phe110 on 
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alpha1 helix (Supp. Figure S9). p.Y123S is the only variant that shows a modest 
decrease in m value that may suggest a modest decrease of the surface area exposed to 
the solvent upon unfolding. The hydroxyl group of p.S161I (Supp. Figure S10) is 
involved in a hydrogen bond with the carboxyl moiety of Glu189 that is lost upon 
substitution with the hydrophobic isoleucine (Supp. Figure S10), as indicated by MD 
simulation. In addition, the nitrogen of the Ser161 peptide bond is hydrogen bonded 
to the hydroxyl group of Ser158. Notably, from MD simulations comes out that the 
residue 161, that was near to Tyr143 and Ser158 in the wild type, in p.S161I is quite 
far from the two residues. The Ser181 residue (Supp. Figure S11), in the wild type 
crystal structure is involved in a network of hydrogen bonds with Glu184, that may be 
lost upon the variation from a polar serine into phenylalanine, hence the effect of the 
amino acid substitution on the FXN structural stability might be related to the 
hydrophobic nature of the phenylalanine side chain (Supp. Figure S11). The mutation 
of residues Asp104, Ala107 and Ser202 does not affect significantly thermodynamic 
stability of FXN and, in the wild type crystal structure, these residues do not engage 
in any specific interactions with other amino acid side chains (Supp. Figure S6, S7 
and S12). Notably, the variants p.D104G, p.A107V, p.S161I, p.S181F and p.S202F 
that show a remarkable inhibition of Fe-S clusters formation involve residues that do 
not form a network of interactions with other side chains (Supp. Figure S6, S7, S10, 
S11 and S12). On the other hand, the variants p.F109L and p.Y123S that affect 
residues involved in a network of interaction with other side chains (Supp. Figure S8 
and S9), are thermodynamically destabilized and show only a partial inhibitor effect 
on Fe-S cluster formation. Notably, the failure to obtain p.W173C as a soluble 
recombinant protein may be ascribed to the disruption of the network of hydrophobic 
interactions caused by the substitution of Trp173 with a cysteine residue (Supp. 
Figure S13). 
The similarities in the spectral properties of the FXN variants with those of the wild 
type suggest that the effect of the mutations is localised to the neighbourhoods of the 
mutated residues, that involve non conserved surface residues, without affecting the 
global protein fold. Indeed, mutations of surface residues are usually well tolerated in 
proteins, they do not significantly affect the global folding and may promote new 
protein functions, though may be destabilizing (Tokuriki and Tawfik, 2009). In the 
case of FXN, the substitution of non conserved and solvent exposed residues, that do 
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not alter the structural global fold, may give rise to a protein with alternative functions 
or promote new protein-protein interactions. The presence of the nsSNVs in some 
particular cancer types may suggest a possible advantage for their expression over the 
wild type in cancer cells. The main question that arise from our results concerns the 
importance of these variants. How a less stable, and apparently less efficient, FXN 
may be an advantage for the metabolic reprogramming of particular cancer cells and, 
more generally, for tumour onset and progression, is still an open question and will be 
a matter of further investigations. 
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FIGURES 
Figure 1. Amino acid sequence and secondary structure elements of FXN. 
(A) The mutated residues (protein seq. ref. NP_000135.2) object of this study and 
reported in COSMIC are depicted in bold red, the residues mutated in FRDA are 
identified by upper black dots. Tyr123 and Trp173 are mutated in FRDA and 
reported in COSMIC. The lower black stars represent the residues involved in iron 
binding. The red line highlights the acidic binding region. The secondary structure 
elements are as reported in 1EKG (Dhe-Paganon et al., 2000). (B) Location of the 
mutations on FXN structure. Mutated residues are depicted in scaled ball and stick. 
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Figure 2. Spectral properties of FXN wild type and variants. (A) Near-UV CD 
spectra were recorded in a 1.0-cm quartz cuvette at 1.1-1.2 mg/mL protein 
concentration. (B) Intrinsic fluorescence emission spectra were recorded at 60-80 
µg/mL variants (0.09 AU280nm, 295 nm excitation wavelength). (C) Far-UV CD 
spectra were recorded in a 0.1-cm quartz cuvette at 103-130 µg/mL. All spectroscopic 
measurements were carried out at 20°C in 20 mM Tris-HCl, pH 8.0 containing 0.1 M 
NaCl and 0.2 mM DTT. 
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Figure 3. Urea-induced equilibrium unfolding of FXN wild type and variants. 
(A) Normalized intensity-averaged emission wavelength ( )λ . (B) Normalized molar 
ellipticity at 222 nm ([Θ222]) reported after removal of the high-frequency noise and 
the low-frequency random error by SVD. The continuous lines represent the nonlinear 
fitting of the normalized ( )λ and [Θ222] data to Eq (3). The reversibility points (empty 
circles) are shown, for clarity, only for the wild type and were not included in the 
nonlinear regression analysis. All spectra were recorded at 20 °C, as described in 
Materials ad Methods.  
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Figure 4. Chevron plots. (A) Chevron plots of human (black squares) and yeast 
frataxin (data from Bonetti et al., 2014, gray circles). Data are fitted with an equation 
that takes into account a broad energy barrier in the transition state. (B) Chevron plots 
of FXN wild type and variants p.D104G, p.A107V, p.F109L, p.Y123S, p.S161I, 
p.S181F, p.S202F in 50 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, pH 8.5, at 37°C. 
A global fit analysis was performed, sharing the mf and mu values for all the data sets 
(see details in the text).  
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Figure 5. Cross-linking. Cross-linking experiments with BS3 to identify the 
interaction between 40 μM IscS and 40 µM FXN wild-type (2) or mutated: p.D104G 
(3), p.A107V (4), p.F109L (5), p.Y123S (6), p.S161I (7), p.S181F (8), p.S202F (9). 
The first lane on the left is the control carried out using isolated IscS (1). The new 
species at ca. 58 kDa corresponds to the complex FXN-IscS. 
 
Figure 6. Cluster formation. Cluster formation rates on IscU (50μM) in the presence 
of 1µM IscS, 3 mM DTT with 250 µM Cys, and 25 µM Fe2+. The curves were 
recorded in the absence (dotted line) or in the presence of 50 μM of FXN wild type 
and variants. Negative values are due to imperfect subtraction from the baseline and 
should be considered as zero (full inhibition). 
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Table 1. Melting temperatures and thermodynamic parameters for urea-induced 
unfolding equilibrium of FXN wild type and variants measured by far-UV CD 
and fluorescence spectroscopy 
Protein 
Variant 
aTm  
(°C) 
b ∆GH2O  
(kcal/mol) 
b m  
(kcal/mol•M) 
c [Urea]0.5
  
(M) 
  
 CD 
([Θ]222) 
Fluorescence 
(λ)  
 CD 
([Θ]222) 
Fluorescence 
(λ) 
CD 
([Θ]222) 
Fluorescenc
e (λ) 
Wild 
type 
71.0 9.23 ± 0.47 9.77 ± 0.40 1.88 ± 
0.10 
2.00 ± 0.08 4.91 4.87 
p.D104G 74.0 9.44 ± 0.46 10.39 ± 0.31 1.82 ± 
0.09 
1.99 ± 0.06 5.20 5.22 
p.A107V 68.0 10.03 ± 
0.91 
9.06 ± 0.22 2.13 ± 
0.19 
1.95 ± 0.05 4.71 4.64 
p.F109L 59.6 7.14 ± 0.34 6.18 ± 0.16 2.09 ± 
0.10 
1.85 ± 0.05 3.42 3.34 
p.Y123S 56.6 4.31 ± 0.18 4.48 ± 0.18 1.60 ± 
0.06 
1.59 ± 0.06 2.69 2.84 
 p.S161I 60.0 5.88 ± 0.58 6.95 ± 0.24 1.88 ± 
0.19 
2.11 ± 0.07 3.12 3.30 
p.S181F 59.9 6.12 ± 0.27 6.86 ± 0.33 1.84 ± 
0.08 
1.99 ± 0.09 3.32 3.45 
p.S202F 70.7 9.07 ±0.32 9.60 ±0.33 1.89 ± 
0.07 
2.18 ± 0.07 4.78 4.40 
aTm values were calculated by taking the first derivative of the ellipticity at 222 nm 
with respect to temperature, as described in the text. Urea-induced unfolding 
equilibrium data were obtained by monitoring the ellipticity at 222 nm ([Θ222]) and 
fluorescence intensity averaged emission wavelength ( λ ), as described in Materials 
and Methods. b∆G
H2O and m values were obtained from Eq (2); c[Urea]0.5 was 
calculated from Eq (4). Data are reported as the mean ± SE of the fit. 
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Table 2. Folding kinetics data for FXN wild type and variants calculated from 
chevron plot fitting. 
 
akf 
(s-1) 
 
amf 
(kcal/ 
mol•M) 
 
aku 
(s-1) 
 
amu 
(kcal/ 
mol•M) 
 
am’ 
(kcal/ 
mol•M) 
 
b∆GN-D 
(kcal/m
ol) 
Wild 
type 
78.5 ± 
5.8 0.64 ± 0.02 
7.8·10-5 ± 
0.8·10-5 1.22 ± 0.06 0.06± 0.01 
8.0 ± 
0.8 
p.D104
G 
84.5 ± 
5.9 0.64 ± 0.02 
3.2·10-5 ± 
0.3·10-5 1.22 ± 0.06 0.06± 0.01 
8.6 ± 
0.9 
p.A107
V 
70.0 ± 
5.4 0.64 ± 0.02 
1.6·10-5 ± 
0.2·10-5 1.22 ± 0.06 0.06± 0.01 
7.5 ± 
0.8 
 
p.F109
L 
57.7 ± 
3.6 0.64 ± 0.02 
1.1·10-5 ± 
0.1·10-5 1.22 ± 0.06 0.06± 0.01 
5.0 ± 
0.5 
p.Y123
S 
43.8 ± 
2.9 0.64 ± 0.02 
3.4·10-5 ± 
0.3·10-5 1.22 ± 0.06 0.06± 0.01 
4.1 ± 
0.4 
 
p.S161I 
21.7 ± 
1.4 0.64 ± 0.02 
1.9·10-5 ± 
0.2·10-5 1.22 ± 0.06 0.06± 0.01 
5.4 ± 
0.5 
p.S181F 
32.7 ± 
2.1 0.64 ± 0.02 
3.0·10-5 ± 
0.3·10-5 1.22 ± 0.06 0.06± 0.01 
5.4 ± 
0.5 
p.S202F 
71.4 ± 
4.9 0.64 ± 0.02 
9.4·10-5 ± 
0.9·10-5 1.22 ± 0.06 0.06± 0.01 
7.9 ± 
0.8 
akf, mf, mf, ku, mu and m’ were calculated from Eq (5). b∆GN-D values were calculated 
from Eq (6) 
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Table 3 – Average r.m.s.d. values computed in the last 50 ns (100 ns) of the 
simulations at 300 K (355 K). 
System ar.m.s.d. 300K ar.m.s.d. 355K bRgyr 300K bRgyr 355K 
Wild type 0.16(1) nm 0.21(4) nm 1.35(1) nm 1.39(1) nm 
p.D104G 0.13(1) nm 0.18(2) nm 1.36(1) nm 1.39(1) nm 
p.A107V 0.14(2) nm 0.23(3) nm 1.36(1) nm 1.40(1) nm 
 p.F109L 0.17(2) nm 0.15(3) nm 1.36(1) nm 1.40(1) nm 
p.Y123S 0.18(1) nm 0.18(2) nm 1.35(1) nm 1.39(1) nm 
 p.S161I 0.13(1) nm 0.21(2) nm 1.36(1) nm 1.40(1) nm 
p.S181F 0.19(2) nm 0.19(2) nm 1.35(1) nm 1.39(1) nm 
p.S202F 0.15(2) nm 0.13(2) nm 1.36(1) nm 1.39(1) nm 
aThe r.m.s.d. is calculated on the backbone of the protein and taking as reference 
structure the one at the end of the equilibration procedure of the wild type simulation. 
bThe average values of the radius of gyration (Rgyr) are computed in the last 50 ns 
(100 ns) of the simulations at 300 K (355 K) considering the backbone of the protein. 
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Table 4. Average distances between Leu136-Ala193 (d1), Leu140-Ala193 (d2) 
and Leu140-Leu194 (d3).  
System d1 (Å) d2 (Å) d3 (Å) 
Wild type 7 ± 1 11 ± 2 16 ± 2 
p.D104G 4 ± 1 5 ± 1 7 ± 3 
p.A107V 4 ± 1 5 ± 1 8 ± 2 
 p.F109L 5 ± 1 6 ± 1 10 ± 2 
p.Y123S 6 ± 2 8 ± 2 15 ± 3 
 p.S161I 4 ± 1 5 ± 1 7 ± 2 
p.S181F 6 ± 1 12 ± 2 17 ± 2 
p.S202F 5 ± 1 5 ± 1 8 ± 2 
Distances and errors were computed along the last 50 ns of the simulations at 300 K. 
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